Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients.

Wojciechowska C, Romuk E, Nowalany-Kozielska E, Jacheć W.

Hellenic J Cardiol. 2017 Sep - Oct;58(5):350-359. doi: 10.1016/j.hjc.2017.03.006. Epub 2017 Mar 28.

2.

Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A, Lupón J.

J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24.

3.

Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.

Wang CH, Yang NI, Liu MH, Hsu KH, Kuo LT.

Cardiol J. 2016;23(5):563-572. doi: 10.5603/CJ.a2016.0053. Epub 2016 Aug 12.

4.

Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.

Hu DJ, Xu J, Du W, Zhang JX, Zhong M, Zhou YN.

Int J Cardiovasc Imaging. 2016 Dec;32(12):1725-1733. Epub 2016 Aug 26.

PMID:
27566192
5.

Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients.

Obokata M, Sunaga H, Ishida H, Ito K, Ogawa T, Ando Y, Kurabayashi M, Negishi K.

Am Heart J. 2016 Sep;179:29-41. doi: 10.1016/j.ahj.2016.05.018. Epub 2016 Jun 18.

PMID:
27595677
6.

The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.

Gawor M, Śpiewak M, Janas J, Kożuch K, Wróbel A, Mazurkiewicz Ł, Baranowski R, Marczak M, Grzybowski J.

Kardiol Pol. 2017;75(10):997-1004. doi: 10.5603/KP.a2017.0118. Epub 2017 Jun 14.

7.

Impact of diabetes on the predictive value of heart failure biomarkers.

Alonso N, Lupón J, Barallat J, de Antonio M, Domingo M, Zamora E, Moliner P, Galán A, Santesmases J, Pastor C, Mauricio D, Bayes-Genis A.

Cardiovasc Diabetol. 2016 Nov 3;15(1):151.

8.

N-terminal pro brain natriuretic peptide to predict prognosis in dilated cardiomyopathy with sinus rhythm.

Tigen K, Karaahmet T, Kahveci G, Tanalp AC, Bitigen A, Fotbolcu H, Bayrak F, Mutlu B, Basaran Y.

Heart Lung Circ. 2007 Aug;16(4):290-4. Epub 2007 Apr 2.

PMID:
17403613
9.

Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.

Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, Zannad F, Whellan DJ, Donahue MP, Piña IL, Adams KF, Kitzman DW, O'Connor CM, Felker GM.

JACC Heart Fail. 2014 Jun;2(3):260-8. doi: 10.1016/j.jchf.2013.12.004.

10.

Profiles of cardiovascular biomarkers according to severity stages of Chagas cardiomyopathy.

Echeverría LE, Rojas LZ, Calvo LS, Roa ZM, Rueda-Ochoa OL, Morillo CA, Muka T, Franco OH.

Int J Cardiol. 2017 Jan 15;227:577-582. doi: 10.1016/j.ijcard.2016.10.098. Epub 2016 Nov 1.

PMID:
27839809
11.

A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.

Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Severin TM, Wang Y, Qian M, Teerlink JR, Metra M, Davison BA, Voors AA.

Eur J Heart Fail. 2017 Aug;19(8):1001-1010. doi: 10.1002/ejhf.749. Epub 2017 Jan 30.

12.

ST2 as a novel prognostic marker in end-stage renal disease patients on hemodiafiltration.

Homsak E, Ekart R.

Clin Chim Acta. 2018 Feb;477:105-112. doi: 10.1016/j.cca.2017.12.006. Epub 2017 Dec 6.

PMID:
29221927
13.

Prognostic utility of anemia and pro-B-type natriuretic peptide in patients with nonischemic dilated cardiomyopathy and normal renal function.

Tigen K, Karaahmet T, Cevik C, Gurel E, Mutlu B, Basaran Y.

Am J Med Sci. 2009 Feb;337(2):109-15. doi: 10.1097/MAJ.0b013e31818128b5.

PMID:
19214026
14.

Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure.

van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Orsel JG, Westenbrink BD, Brunner-la Rocca HP, van Miltenburg AJM, Boersma E, Hillege HL, Akkerhuis KM; TRIUMPH Investigators.

J Am Coll Cardiol. 2017 Nov 7;70(19):2378-2388. doi: 10.1016/j.jacc.2017.09.026.

15.

High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure.

Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP.

Circ Heart Fail. 2011 Mar;4(2):180-7. doi: 10.1161/CIRCHEARTFAILURE.110.958223. Epub 2010 Dec 22.

16.

Usefulness of Serial N-terminal Pro-B-type Natriuretic Peptide Measurements to Predict Cardiac Death in Acute and Chronic Dilated Cardiomyopathy in Children.

den Boer SL, Rizopoulos D, du Marchie Sarvaas GJ, Backx AP, Ten Harkel AD, van Iperen GG, Rammeloo LA, Tanke RB, Boersma E, Helbing WA, Dalinghaus M.

Am J Cardiol. 2016 Dec 1;118(11):1723-1729. doi: 10.1016/j.amjcard.2016.08.053. Epub 2016 Aug 30.

PMID:
27692597
17.

Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.

Mueller T, Gegenhuber A, Leitner I, Poelz W, Haltmayer M, Dieplinger B.

Clin Chim Acta. 2016 Dec 1;463:158-164. doi: 10.1016/j.cca.2016.10.034. Epub 2016 Oct 29.

18.

ST2 pathogenetic profile in ambulatory heart failure patients.

Bayes-Genis A, Januzzi JL, Gaggin HK, de Antonio M, Motiwala SR, Zamora E, Galán A, Domingo M, Urrutia A, Lupón J.

J Card Fail. 2015 Apr;21(4):355-61. doi: 10.1016/j.cardfail.2014.10.014. Epub 2014 Nov 3.

PMID:
25451702
19.

Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.

Pfetsch V, Sanin V, Jaensch A, Dallmeier D, Mons U, Brenner H, Koenig W, Rothenbacher D.

Cardiovasc Drugs Ther. 2017 Apr;31(2):167-177. doi: 10.1007/s10557-017-6718-1.

PMID:
28283847
20.

Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study.

Truong QA, Januzzi JL, Szymonifka J, Thai WE, Wai B, Lavender Z, Sharma U, Sandoval RM, Grunau ZS, Basnet S, Babatunde A, Ajijola OA, Min JK, Singh JP.

Heart Rhythm. 2014 Dec;11(12):2167-75. doi: 10.1016/j.hrthm.2014.07.007. Epub 2014 Jul 8.

Supplemental Content

Support Center